{"classes":[{"categories":[{"measurements":[{"comment":"Values were non-estimable (insufficient number of participants with events).","groupId":"OG000","lowerLimit":"46.1","upperLimit":"NA","value":"57.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable Population: all participants who received ≥1 dose of avapritinib, were deemed evaluable per mIWG-MRT-ECNM criteria at baseline as assessed by study steering committee review and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments and had been on study for ≥6 cycles; had an end of study visit.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 65","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}